100,000 Shares in Avalo Therapeutics, Inc. $AVTX Purchased by Patient Square Capital LP

Patient Square Capital LP bought a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $1,271,000. Avalo Therapeutics accounts for 0.3% of Patient Square Capital LP’s portfolio, making the stock its 22nd biggest position.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Nantahala Capital Management LLC lifted its position in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after purchasing an additional 95,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares during the period. Bank of America Corp DE lifted its holdings in Avalo Therapeutics by 7,066.8% during the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after buying an additional 400,898 shares in the last quarter. Velan Capital Investment Management LP boosted its position in Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock valued at $773,000 after buying an additional 43,000 shares during the period. Finally, Geode Capital Management LLC boosted its position in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after buying an additional 2,648 shares during the period. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AVTX has been the topic of several analyst reports. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Guggenheim initiated coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Avalo Therapeutics in a research note on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.88.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $14.21 on Monday. The business has a 50-day moving average of $16.30 and a two-hundred day moving average of $14.72. The company has a market capitalization of $263.03 million, a price-to-earnings ratio of -2.65 and a beta of 0.88. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $20.72.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.